Compound ID | 1221
Cefepime/VNRX-5133
Class: Beta-lactamase inhibitor (broad spectrum)
| Spectrum of activity: | Gram-negative |
| Details of activity: | multi-drug resistant (MDR) gram-negative bacterial infections, including Carbapenem-resistant Enterobacteriaceae (CRE) and Carbapenem-resistant Pseudomonas aeruginosa(CRPA). |
| Institute where first reported: | VenatoRx Pharmaceuticals |
| Highest developmental phase: | Phase 2 |
| Development status: | Active |
| External links: | |
| Guide to Pharmacology: | cefepime |
| Main Source: | https://www.venatorx.com/pipeline/ |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us.
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.